Among non-small-cell lung cancer (NSCLC) patients that are non-smokers, 15-50% have EGFR mutations and 15-25% have K-Ras mutations, both of which play an important role in tumor progression and metastasis [67, 68]. Here, KRAS is linked to neoplasm.